Bridge Biotherapeutics, Inc. (KOSDAQ:288330)

South Korea flag South Korea · Delayed Price · Currency is KRW
739.00
+59.00 (8.68%)
At close: Jun 17, 2025, 3:30 PM KST
-62.42%
Market Cap 43.27B
Revenue (ttm) 11.18M
Net Income (ttm) -19.27B
Shares Out 52.19M
EPS (ttm) -428.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,094,562
Average Volume 2,793,633
Open 692.00
Previous Close 680.00
Day's Range 680.00 - 761.00
52-Week Range 671.00 - 9,280.00
Beta 0.89
RSI 35.21
Earnings Date Aug 10, 2025

About Bridge Biotherapeutics

Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration wit... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 35
Stock Exchange KOSDAQ
Ticker Symbol 288330
Full Company Profile

Financial Performance

In 2024, Bridge Biotherapeutics's revenue was 2.18 million, a decrease of -97.82% compared to the previous year's 100.00 million. Losses were -19.76 billion, -53.32% less than in 2023.

Financial Statements

News

There is no news available yet.